Key result
CRISPR-Cas12a DETECTR assay detects Influenza A and B without cross-reactivity in ~75 minutes.
Why the study?
A rapid and accurate on-site diagnostic test for influenza A and B viruses is critical for preventing the spread of infectious diseases but specific detection methods are needed.
Does a CRISPR-Cas12a-based assay coupled with RT-RPA/RT-LAMP accurately and rapidly detect Influenza A and B viruses?
Does a CRISPR-Cas12a-based assay coupled with RT-RPA/RT-LAMP accurately and rapidly detect Influenza A and B viruses?
A novel CRISPR-Cas12a-based assay coupled with isothermal amplification provides rapid, specific, and sensitive detection of Influenza A and B viruses.
No takes yet. Share an insight, caveat, or question.
May support rapid point-of-care influenza testing; leaves open validation in human clinical samples.
Park et al. (2021) studied Influenza A and B virus infection. CRISPR-Cas12a-based DETECTR assay was evaluated on Detection limit of IAV and IBV titers. A CRISPR-Cas12a-based DETECTR assay detected Influenza A and B viruses at titers as low as 1 PFU per reaction within 75 to 85 minutes without cross-reactivity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: